若生智能
Drug Database
RA

rabies vaccine

✓ Approved

China National Biotec Group · 疫苗 · 疫苗

什么是 rabies vaccine？

rabies vaccine 是一种疫苗，由China National Biotec Group研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司China National Biotec Group
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, China National Biotec Group

治疗适应症

rabies vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsRabies✓ Approved

相关研究文献

PubMedTropical medicine and infectious disease2026-07-27

Evaluation of Bait Acceptance and Immune Response in a Local Dog Population During an Oral Rabies Vaccination Field Study in Cambodia.

Tep Bengthay B, Hak Sochetra S, Sophorn Nouv N, Grandy Sin S et al.

(1) Background: Dog-mediated human rabies remains a serious public health problem in Cambodia, partially due to the high abundance of dogs. As most dogs are free-roaming and cannot easily be handled and restrained, the rabies vaccination coverage is very low. Oral rabies vaccination (ORV) could increase the vaccination coverage to levels required for interrupting the transmission cycle. (2) Methods: In this study, the bait acceptance and immunogenicity of a commercially available vaccine bait were tested in local free-roaming dogs in the northern part of Takeo province in Cambodia. (3) Results: In total, 75.4% (515/683) of dogs initially showed interest when offered an egg-flavored bait containing the SPBN GASGAS rabies virus vaccine. Subsequently, 89.9% of these dogs consumed the bait, and almost all of them (98.3%) were considered successfully vaccinated. Blood samples were collected from 50 dogs prior to vaccination. Eight of these fifty dogs tested sero-positive for rabies antibodies (ELISA) and were excluded from follow-up samples. Thirty and ninety days post-vaccination, 91.4% and 68.2% of the relocated vaccinated dogs tested sero-positive, respectively. (4) Conclusions: Bait acceptance and immunogenicity showed similar results as observed in studies with the same vaccine bait conducted in other countries. Hence, ORV seems to be a very promising tool for dog rabies control in Cambodia, which has a large owned but free-roaming dog population.

PMID 42506773
阅读全文 →
PubMedVaccines2026-07-27

A Multi-State, Cross-Sectional Retrospective Study on Knowledge, Attitude and Practice of Rabies Post-Exposure Prophylaxis Including Rabies Monoclonal Antibody Among Physicians Across India.

Shankaraiah Ravish Haradanahalli RH, N S Navyashree N, G Divya Bharathi DB, Dutta Trayambak T et al.

Rabies remains a lethal vaccine-preventable disease in India, and physicians managing animal-bite cases are central to effective post-exposure prophylaxis (PEP). With the increasing use of rabies monoclonal antibodies (RmAbs) as alternatives to conventional rabies immunoglobulins, this study assessed physicians' knowledge, attitude, and practice (KAP) regarding rabies PEP, including RmAb awareness and acceptance. This multi-state, cross-sectional retrospective KAP survey was conducted among 208 physicians across ten Indian states using a structured, self-administered Google Form. The 33-item questionnaire assessed Knowledge, Attitude, and Practice domains, with 11 items each, scored binarily according to NCDC guidelines. Descriptive statistics, Shapiro-Wilk normality testing, Kruskal-Wallis tests with post hoc corrections, and Spearman rank-order correlations were performed. Mean domain scores were 8.00/11 for Knowledge (72.7%), 7.22/11 for Attitude (65.6%), and 8.64/11 for Practice (78.5%). Key gaps were identified in the intramuscular pre-exposure prophylaxis schedule, management of excess RIG/RmAb after wound infiltration, exposure categorization of animal contact, and vaccine administration site in young children. The Knowledge-Practice correlation was moderately strong and statistically significant (r = 0.520, p < 0.001). Acceptance of RmAbs was high, with 88.5% recognizing them as effective replacements for RIGs and 84.6% considering them safer than RIGs. Practice scores showed the most consistent improvement, Knowledge scores improved on most items but declined sharply for the pre-exposure prophylaxis schedule, and Attitude scores showed a mixed pattern of gains and losses compared with the 2013 benchmark survey. Overall KAP scores were adequate, with Practice scoring highest. Targeted continuing medical education focused on NCDC guidelines and practical PEP scenarios is needed among physicians managing rabies exposures.

PMID 42506672
阅读全文 →
PubMedVaccines2026-07-27

Inactivation of Wild Poliovirus with β-Propiolactone.

Kovpak Anastasia A, Pashkov Sergey S, Kostrova Mariia M, Nebesnyi Kirill K et al.

Antiviral vaccines are usually created by inactivating viruses using physical or chemical methods. Inactivation of poliovirus with β-propiolactone (BPL) has advantages, including the absence of a requirement for long-term incubation with the inactivating agent, which minimizes the risk of negative effects of the potentially dangerous substance on the virus and reduces the duration of the inactivation process. BPL was applied at 0.2% (w/v) concentration under two conditions: 4 °C for 24 h and 37 °C for 3 h. Inactivation completeness was confirmed on Vero cell culture, while immunogenicity was assessed in guinea pigs via neutralizing antibody test. Two variants of virus inactivation made it possible to obtain inactivated samples that retained their immunogenic properties. BPL-inactivated samples retained sufficient D-antigen levels and elicited neutralizing antibodies comparable to or exceeding those from formaldehyde-inactivated controls. The inactivation method at 37 °C provided faster inactivation, while at 4 °C it provided a smooth decrease in virus titer. These results confirm that β-propiolactone is a viable alternative to formaldehyde for the production of inactivated polio vaccine (IPV), providing rapid inactivation of the virus compared to inactivation with formaldehyde while maintaining immunogenicity, as confirmed by guinea pig control.

PMID 42506679
阅读全文 →
PubMedDiseases (Basel, Switzerland)2026-07-27

From Pandemic Innovation to Platform Diversification: A Systematic Review of Clinical and Preclinical Development of Non-SARS-CoV-2 mRNA Vaccines.

Hudu Shuaibu Abdullahi SA, Alruwaili Muhannad M, Soliman Mohamed M, Morad Emad A EA et al.

Background: Messenger RNA (mRNA) vaccines have emerged as a versatile platform beyond SARS-CoV-2, with expanding applications in infectious diseases and oncology. However, comprehensive evidence synthesis of non-SARS-CoV-2 mRNA vaccines remains limited. Methods: This systematic review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD420261323500). MEDLINE, Embase, Web of Science, Scopus, ClinicalTrials.gov, and WHO ICTRP were systematically searched for studies published between 1 January 2000 and 28 February 2026. Eligible studies included phase I-III clinical trials and in vivo preclinical studies evaluating non-SARS-CoV-2 mRNA vaccines. Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2, ROBINS-I, and SYRCLE tools. Findings were synthesized narratively because of substantial heterogeneity. Results: A total of 40 studies met the eligibility criteria and were included in the review, comprising 20 clinical studies and 20 preclinical studies. Advanced clinical programs targeted influenza and respiratory syncytial virus (RSV), with phase III trials displaying seroconversion rates above 70% with good safety profiles. Preliminary phase I studies for HIV, cytomegalovirus, rabies, and personalized cancer mRNA vaccines showed promising humoral and cellular immune responses. Preclinical studies showed strong antibody and T-cell responses against malaria, tuberculosis, Group B Streptococcus, and Zika virus. Most adverse events were mild to moderate, while serious vaccine-related adverse events were uncommon. Conclusions: Non-SARS-CoV-2 mRNA vaccines demonstrate substantial translational potential across infectious disease and oncology applications. Although the vaccine candidates have demonstrated promising immunogenicity and safety, most are in the early stages of development. This highlights the need for large trials, long-term safety follow-up and better global representation.

PMID 42505558
阅读全文 →
PubMedZhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi2026-07-27

[Epidemiological trends and spatiotemporal distribution of rabies in China, 2010-2024].

Lyu S M SM, Chen X X, Zhang J H JH, Mu D D et al.

Objective: To characterize the temporal trends and spatiotemporal distribution of human rabies in China from 2010 to 2024, and provide evidence for identification of priority control areas, detection of emerging epidemic areas, and development of targeted prevention strategies. Methods: The incidence data of rabies were collected during 2010-2024 from Infectious Disease Reporting Information Management System of Chinese Disease Prevention and Control Information System.Temporal trend was analyzed by using Joinpoint regression 4.9.1 software. Spatial autocorrelation at the county level was evaluated by using software ArcGIS 10.8. Spatiotemporal clustering was identified by using software SaTScan 9.3, and seasonal pattern was analyzed by using circular distribution method. Results: A total of 10 958 rabies cases were reported in China during the study period with a mean annual incidence rate of 0.05/100 000. The incidence of rabies declined markedly (average annual percent change=-7.55%, t=-5.36,P<0.001). The rabies incidence exhibited clear seasonality, with 5 398 cases (49.26%) occurring between July and November, and a noticeable delay in incidence peak and epidemic period was observed during 2019-2024. Men (7 743 cases) were mainly affected compared with women (3 215 cases), the difference was significant (χ2=111.06, P<0.001). The majority of cases were aged 15-64 years (63.16%), the proportion of the cases in those aged ≥65 years increased substantially from 17.75% to 39.29% with a peak of 44.36%. The majority of the cases were farmers (71.47%). The top three provinces in terms of cumulative cases were Guangxi Zhuang Autonomous Region (1 428 cases), Hunan Province (1 109 cases), and Guangdong Province (1 049 cases). In 2024, up to 90.98% (111/122) of the affected counties were historical epidemic areas. Spatial autocorrelation analysis revealed significant clustering (Moran's I: 0.05-0.28, P<0.001), the hotspots were mainly in southwestern and southern China, showing a northward expansion. Spatiotemporal scanning analysis identified six statistically significant clustering areas, mainly located in interprovincial border areas. No new clustering areas were detected after February 2016. Conclusions: From 2010 to 2024, the human rabies incidence in China declined substantially, with a change of wide transmission to low-level sporadic pattern. High-risk areas shifted northward, with more transmission in historical epidemic areas. Middle-aged and older male farmers remained the most affected population, indicating that it is necessary to target the areas and populations at high risk and improve the resource allocation based on current comprehensive prevention and control measures to further reduce the incidence of rabies.

PMID 42503961
阅读全文 →
PubMedVaccines2026-07-27

Development of a New Feline Combination Vaccine Including a Novel RNA Particle Vaccine Against Feline Leukemia Virus.

Huisman Willem W, Mommen Aart A, Basten Stephanie S, Driessen Kim K et al.

We describe the rationale, design and evaluation of a novel feline combination vaccine (Nobivac® NXT HCPChFeLV) incorporating RNA particle technology against feline leukemia virus (FeLV) alongside live attenuated components for feline herpesvirus-1 (FHV), feline calicivirus (FCV), feline panleukopenia (FPL) and Chlamydia felis. Efficacy and safety outcomes from laboratory and field studies are presented. Nobivac NXT HCPChFeLV is a 0.5 mL, non-adjuvanted, lyophilized vaccine containing live attenuated FHV, FCV, FPL, and C. felis strains, and an alphavirus replicon-derived RNA particle expressing FeLV envelope glycoprotein (gp85). The primary vaccination schedule involved subcutaneous vaccination at 8-9 weeks of age with a booster 4 weeks later. Onset-of-immunity studies were performed 1 week post primary vaccination. Duration-of-immunity studies evaluated challenge both at 1 year and 3 years after primary vaccination with a booster at 1 year (FHV, FCV, FeLV); FPL duration was assessed at 3 years after primary vaccination; C. felis duration was assessed at 1 year. Clinical signs of disease, survival, leukopenia (FPL) and pathogen excretion were assessed. Safety was assessed in laboratory overdose/repeat-dose studies and in a field study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen. Vaccination significantly reduced clinical disease following FHV, FCV and C. felis challenge and reduced FHV-associated mortality. Vaccinated cats were protected from FPL clinical disease, mortality, leukopenia, and FPL excretion. Persistent FeLV antigenemia was significantly prevented after primary vaccination and in 1-year-duration-of-immunity studies and was reduced 3 years after revaccination. The excretion of FHV, FCV and C. felis was significantly reduced in vaccinates vs controls. No serious adverse events were observed in laboratory studies; field vaccination was well tolerated with no injection-site reactions reported. Nobivac NXT HCPChFeLV provides robust, long-lasting protection against multiple feline pathogens, reduced pathogen shedding and demonstrated a favorable safety profile, supporting its use in feline preventive healthcare.

PMID 42506662
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rabies vaccine